Last reviewed · How we verify
CAPEOX/Capecitabine
Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival.
Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival. Used for Metastatic colorectal cancer (in combination with oxaliplatin as CAPEOX), Metastatic breast cancer, Gastric cancer.
At a glance
| Generic name | CAPEOX/Capecitabine |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | Antimetabolite; Fluoropyrimidine |
| Target | Thymidylate synthase; DNA/RNA synthesis |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and cellular enzymatic conversion to its active form, 5-fluorouracil (5-FU). 5-FU acts as an antimetabolite by inhibiting thymidylate synthase, blocking dTMP synthesis and thus DNA replication, while also incorporating into RNA to disrupt protein synthesis. This dual mechanism leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer (in combination with oxaliplatin as CAPEOX)
- Metastatic breast cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Hand-foot skin reaction (palmar-plantar erythrodysesthesia)
- Diarrhea
- Nausea
- Vomiting
- Stomatitis
- Fatigue
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (PHASE2)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma (PHASE2)
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer (PHASE1)
- Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (PHASE2)
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (PHASE2)
- Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAPEOX/Capecitabine CI brief — competitive landscape report
- CAPEOX/Capecitabine updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI